drugset / Trial / NCT00216047
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
Phase 1/2
Terminated
7 enrolled
Hoosier Cancer Research Network
Novartis Pharmaceuticals · collabWalther Cancer Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of HER2 and VEGF enhances response in xenograft models. The upregulation of VEGF in HER2-overexpressing breast cancers may contribute to the aggressive phenotype observed in HER2-positive breast cancer. New therapeutics targeting VEGF and/or its receptors may enhance the efficacy of trastuzumab monotherapy. This trial will investigate the safety and efficacy of combined HER2 and VEGF inhibition.
Timeline
- Start
- 2005-01
- Primary completion
- 2006-08
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | vatalanib | Small molecule | — | — |